209 related articles for article (PubMed ID: 26317139)
1. Part 1. Basic approaches and perspectives.
Handb Exp Pharmacol; 2015; 228():1-3. PubMed ID: 26317139
[No Abstract] [Full Text] [Related]
2. Preface to cognitive enhancement.
Kantak KM; Wettstein JG
Handb Exp Pharmacol; 2015; 228():v. PubMed ID: 26317138
[No Abstract] [Full Text] [Related]
3. Part II. Cognitive domains for pharmacological intervention: implications for neuropsychiatric and neurological illnesses.
Handb Exp Pharmacol; 2015; 228():157-9. PubMed ID: 26317140
[No Abstract] [Full Text] [Related]
4. Signaling pathways relevant to cognition-enhancing drug targets.
Ménard C; Gaudreau P; Quirion R
Handb Exp Pharmacol; 2015; 228():59-98. PubMed ID: 25977080
[TBL] [Abstract][Full Text] [Related]
5. Methods for delivering and evaluating the efficacy of cognitive enhancement.
Harvey PD; Keefe RS
Handb Exp Pharmacol; 2015; 228():5-25. PubMed ID: 25977078
[TBL] [Abstract][Full Text] [Related]
6. Role of adult hippocampal neurogenesis in cognition in physiology and disease: pharmacological targets and biomarkers.
Costa V; Lugert S; Jagasia R
Handb Exp Pharmacol; 2015; 228():99-155. PubMed ID: 25977081
[TBL] [Abstract][Full Text] [Related]
7. Executive function.
Talpos J; Shoaib M
Handb Exp Pharmacol; 2015; 228():191-213. PubMed ID: 25977083
[TBL] [Abstract][Full Text] [Related]
8. Social cognition.
Patin A; Hurlemann R
Handb Exp Pharmacol; 2015; 228():271-303. PubMed ID: 25977087
[TBL] [Abstract][Full Text] [Related]
9. Animal paradigms to assess cognition with translation to humans.
Wallace TL; Ballard TM; Glavis-Bloom C
Handb Exp Pharmacol; 2015; 228():27-57. PubMed ID: 25977079
[TBL] [Abstract][Full Text] [Related]
10. Attention.
Callahan PM; Terry AV
Handb Exp Pharmacol; 2015; 228():161-89. PubMed ID: 25977082
[TBL] [Abstract][Full Text] [Related]
11. Verbal memory.
Sumiyoshi T
Handb Exp Pharmacol; 2015; 228():237-47. PubMed ID: 25977085
[TBL] [Abstract][Full Text] [Related]
12. Emotional memory.
Nader K
Handb Exp Pharmacol; 2015; 228():249-70. PubMed ID: 25977086
[TBL] [Abstract][Full Text] [Related]
13. THC for age-related cognitive decline?
Sarne Y
Aging (Albany NY); 2018 Nov; 10(12):3628-3629. PubMed ID: 30420585
[No Abstract] [Full Text] [Related]
14. Closing thoughts for cognitive enhancement.
Kantak KM; Wettstein JG
Handb Exp Pharmacol; 2015; 228():451-9. PubMed ID: 25977093
[TBL] [Abstract][Full Text] [Related]
15. The Role of Docosahexaenoic Acid (DHA) on Cognitive Functions in Psychiatric Disorders.
Ciappolino V; Mazzocchi A; Botturi A; Turolo S; Delvecchio G; Agostoni C; Brambilla P
Nutrients; 2019 Apr; 11(4):. PubMed ID: 30986970
[TBL] [Abstract][Full Text] [Related]
16. Declarative memory.
Riedel WJ; Blokland A
Handb Exp Pharmacol; 2015; 228():215-36. PubMed ID: 25977084
[TBL] [Abstract][Full Text] [Related]
17. Experts urge smart thinking on cognitive enhancers.
Morris K
Lancet Neurol; 2008 Jun; 7(6):476-7. PubMed ID: 18485312
[No Abstract] [Full Text] [Related]
18. Neural targets in the study and treatment of social cognition in autism spectrum disorder.
Vahabzadeh A; Landino SM; Finger BC; Carlezon WA; McDougle CJ
Handb Exp Pharmacol; 2015; 228():309-34. PubMed ID: 25977088
[TBL] [Abstract][Full Text] [Related]
19. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457.
Callaghan CK; Hok V; Della-Chiesa A; Virley DJ; Upton N; O'Mara SM
Neuropharmacology; 2012 Oct; 63(5):890-7. PubMed ID: 22766392
[TBL] [Abstract][Full Text] [Related]
20. New drug development for cognitive enhancement in mental health: challenges and opportunities.
Insel T; Krystal J; Ehlers M
Neuropharmacology; 2013 Jan; 64():2-7. PubMed ID: 23145450
[No Abstract] [Full Text] [Related]
[Next] [New Search]
